MB
Mark E. Bunnage (EVP, Chief Scientific Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $1.8M of VRTX (3,619 sh across 2 lots, as filed), executed Feb 17. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.0M
shares × price, as filed
Last traded
Feb 25
Filed Feb 26
Median ADV $756.7M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
VRTX
Vertex Pharmaceuticals Incorporated
VRTX · 0 buys · 3 sells
3 filings
Recent filings
VRTXSALE
Vertex Pharmaceuticals Incorporated
View filing →
$302K620 sh × $486.35
Exec Feb 25
Filed Feb 26 · 5:30 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated View filing → $1.8M
3,619 sh across 2 lots
Exec Feb 17
Filed Feb 19 · 5:30 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated View filing → $931K
2,021 sh × $460.43
Exec Feb 11
Filed Feb 12 · 5:30 PM ET